Table 3.
Adjusted Postintervention Differences at Follow-Up for Cardiovascular Disease Clinical Indicators, Project HEART, El Paso, Texas, 2005-2008
| Clinical Indicator | Control Group 4-Month Follow-Upa (n = 126) | Experimental Group 4-Month Follow-Upa (n = 158) | P Valueb |
|---|---|---|---|
| Body mass index, kg/m2 | 31.3 (6.7) | 31.1 (6.3) | .28 |
| Weight, lb | 181.1 (44.2) | 180.5 (37.5) | .44 |
| Waist circumference, in | 41.0 (5.9) | 40.4 (5.7) | .09 |
| Framingham risk scorec | 9.5 (6.7) | 10.4 (7.8) | .26 |
| Metabolic syndrome, mean no. of risk factors | 2.6 (1.2) | 2.7 (1.2) | .32 |
| LDL cholesterol, mg/dL | 123.0 (33.8) | 118.6 (37.8) | .20 |
| HDL cholesterol, mg/dL | 41.5 (11.2) | 41.6 (10.2) | .98 |
| Total cholesterol, mg/dL | 195.2 (42.7) | 189.5 (54.5) | .16 |
| Non-HDL cholesterol, mg/dL | 152.4 (43.4) | 146.3 (42.3) | .10 |
| Triglyceride level, mg/dL | 139.3 (94.5) | 143.6 (78.6) | .64 |
| Fasting blood glucose, mg/dL | 102.7 (42.2) | 101.9 (39.8) | .80 |
| HbA1c, % | 6.6 (1.4) | 6.5 (1.4) | .09 |
| Systolic blood pressure, mm Hg | 130.5 (16.7) | 132.6 (19.4) | .20 |
| Diastolic blood pressure, mm Hg | 75.5 (10.6) | 79.8 (9.3) | <.001 |
Abbreviations: HEART, Health Education Awareness Research Team; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c.
Parenthetical values represent the standard deviations.
Between-groups analysis of covariance for the postintervention follow-up values were adjusted for baseline value, self-reported birthplace, language chosen for baseline survey, years of residence in United States, educational attainment, and financial status.
Framingham score based on age, LDL and HDL cholesterol levels, smoking status, diabetes diagnosis (self-report, HbA1c >7%, or fasting blood glucose >126 mg/dL).